TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12698305
Drug: Retigabine (RGB)
Normalized name: retigabine
DrugBank: Ezogabine (DB04953)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Retigabine (RGB) 200 mg single oral doses on day 1 and day 7, and Lamotrigine (LTG) 25 mg o.i.d. on days 3-8
Study: 12698305
Drug: Lamotrigine (LTG)
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine (LTG) 200 mg single oral doses on day 1 and day 17, and up-titrated to 300 mg RGB b.i.d. on days 6-20
Study: 1745707
Drug: Caffeine (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (1, 2, 3, and 4 mg/kg body weight)
Study: 26606271
Drug: 1.5 g·kg⁻¹·h⁻¹
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g·kg⁻¹·h⁻¹ glucose (GLU)
Study: 26606271
Drug: 1.2 g·kg⁻¹·h⁻¹
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g·kg⁻¹·h⁻¹ glucose + 0.3 g·kg⁻¹·h⁻¹ fructose (GLU + FRU)
Study: 26606271
Drug: 0.9 g·kg⁻¹·h⁻¹
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 g·kg⁻¹·h⁻¹ glucose + 0.6 g·kg⁻¹·h⁻¹ sucrose (GLU + SUC)
Study: 18277739
Drug: Oral-B CrossAction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-B CrossAction manual toothbrush + Crest Pro-Health dentifrice (0.454% stannous fluoride/sodium hexametaphosphate)
Study: 18277739
Drug: Oral-B ProfessionalCare
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-B ProfessionalCare Series 8000 power toothbrush + Pro-Health dentifrice
Study: 18277739
Drug: ProfessionalCare power
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProfessionalCare power brush + Pro-Health dentifrice + Oral-B Hummingbird power flosser
Study: 10577995
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 4 mg, 8 mg, 16 mg
Study: 12660683
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (all doses)
Study: 8767620
Drug: defibrotide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: defibrotide (400 mg bid)
Study: 8767620
Drug: heparan-sulfate (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: heparan-sulfate (40 mg bid)
Study: 7036914
Drug: Potassium supplements
Normalized name: POTASSIUM SUPPLEMENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium supplements (group A, n = 10)
Study: 26502850
Drug: Capecitabine maintenance
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine maintenance therapy (oral capecitabine 1,250 mg/m2 twice daily on days 1-14 every 3 weeks)
Study: 23081843
Drug: Gentamicin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (10 mg) added to contrast medium
Study: 22919877
Drug: Intravenous pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pantoprazole (PPI) 80 mg + 8 mg/h for 72 hours
Study: 11094036
Drug: Intra-arterial infusion
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusion of [(3)H]L-arginine (100 nCi/min)
Study: 11094036
Drug: [(3)H]L-arginine uptake
Approvals — FDA: no, EMA: no, PMDA: no
Description: [(3)H]L-arginine uptake by peripheral blood mononuclear cells (PBMCs)
Study: 1618242
Drug: Sustained-release nicardipine
Normalized name: nicardipine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release nicardipine 45-60 mg/d
Study: 16395953
Drug: Antidepressant drug
Normalized name: MAO A Inhibitors, antidepressant drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant drug treatment
Study: 17929555
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) and aspirin; n = 20
Study: 17929555
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without GH or aspirin; n = 20
Study: 12131260
Drug: 20 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g/d bovine colostrum + 40 g whey protein concentrate (wpc)
Study: 9204351
Drug: iopentol 300
Normalized name: iopentol 300 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: iopentol 300 mg I/ml
Study: 31290747
Drug: 1-day intravenous
Normalized name: ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-day intravenous antibiotics (cefmetazole and metronidazole)
Study: 31290747
Drug: 4-day intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-day intravenous and oral antibiotics (cefmetazole and metronidazole)
Study: 31290747
Drug: 1-day intravenous
Normalized name: ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-day intravenous antibiotics
Study: 31290747
Drug: 4-day intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-day intravenous and oral antibiotics
Study: 23471413
Drug: JNJ‐39588146 (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ‐39588146 (any dose)
Study: 20803860
Drug: 0.5% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% levobupivacaine 7.5 mg (Group I)
Study: 20803860
Drug: 0.5% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% levobupivacaine 10 mg (Group II)
Study: 20803860
Drug: 0.5% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% levobupivacaine 12.5 mg (Group III)
Study: 20803860
Drug: 0.5% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% levobupivacaine 15 mg (Group IV)
Study: 7707407
Drug: Standard radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard radiation therapy (60 Gy delivered at 2 Gy per fraction, 5 days a week, over a 6-week period)
Study: 7707407
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (cisplatin 100 mg/m2 on days 1 and 29, vinblastine 5 mg/m2 per week for 5 weeks) followed by standard radiation therapy (starting on day 50)
Study: 7707407
Drug: Hyperfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiation therapy (69.6 Gy delivered at 1.2 Gy per fraction twice daily)
Study: 25351561
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of daidzein
Study: 25351561
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of genistein
Study: 25351561
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of soy protein plus no addition
Study: 9062602
Drug: Pethidine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine (0.1 ml, 10 mg/ml) combined with lidocaine (3 ml, 2%)
Study: 9062602
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (0.1 ml) combined with lidocaine (3 ml, 2%)
Study: 22734388
Drug: Combined Therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Therapy (Acupotomy + Blood Pricking)
Study: 20668051
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1500 mg Ca/d from 20 weeks of gestation until delivery)
Study: 18346640
Drug: anti-CD25 monoclonal
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-CD25 monoclonal antibody (Daclizumab)
Study: 11956046
Drug: Salbutamol 100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol 100, 100, and 200 microg inhaled at 5-minute intervals after exercise
Study: 7636536
Drug: Dexverapamil 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexverapamil 120 mg/m2 plus vinblastine 0.11 mg/kg IV on days 1 and 2 every 21 days
Study: 7636536
Drug: Dexverapamil 180
Normalized name: verapamil hydrochloride 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexverapamil 180 mg/m2 plus dexamethasone plus vinblastine 0.11 mg/kg IV on days 1 and 2 every 21 days
Study: 326013
Drug: 1 Gm.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 Gm. of ASA daily
Study: 26536443
Drug: Preoperative cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative cognitive-behavioral therapy (CBT)
Study: 24308723
Drug: Long-acting testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting testosterone undecanoate (TU) 1,000 mg
Study: 23346766
Drug: Group IV
Normalized name: Corticosteroids, very potent (group IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group IV (20 ml dexamethasone at 0.5 mg/ml, injected over 30s)
Study: 23346766
Drug: Group I
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I (2 ml dexamethasone at 5 mg/ml, injected over 5s)
Study: 23346766
Drug: Group II
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II (4 ml dexamethasone at 2.5 mg/ml, injected over 5s)
Study: 23346766
Drug: Group III
Normalized name: Corticosteroids, potent (group III)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group III (10 ml dexamethasone at 1 mg/ml, injected over 5s)
Study: 20516633
Drug: Etidronate (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidronate (20 mg/kg/day for 12 weeks)
Study: 20516633
Drug: Indomethacin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (75 mg/day for 2 weeks)
Study: 18612156
Drug: Capecitabine as
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine as second treatment (1,250 mg/m² twice daily, days 1 through 14)
Study: 18612156
Drug: Capecitabine as
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine as first treatment (1,250 mg/m² twice daily, days 1 through 14)
Study: 18612156
Drug: FU/LV as
Approvals — FDA: no, EMA: no, PMDA: no
Description: FU/LV as first treatment (425 mg/m² FU, 45 mg LV, once weekly for 6 weeks)
Study: 18612156
Drug: FU/LV as
Approvals — FDA: no, EMA: no, PMDA: no
Description: FU/LV as second treatment (425 mg/m² FU, 45 mg LV, once weekly for 6 weeks)
Study: 6313458
Drug: Cimetidine, 200
Normalized name: Cimetidine, 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine, 200 mg three times a day and 400 mg at night
Study: 29208190
Drug: Three-session, manualised,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-session, manualised, psychosocial, gender-specific group intervention plus BBV transmission information booklet and treatment as usual (TAU)
Study: 22565002
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg/d plus Everolimus 10 mg/d
Study: 22565002
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg/d alone
Study: 17469692
Drug: Cholinesterase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinesterase inhibitors (especially donepezil)
Study: 17469692
Drug: NMDA receptor
Normalized name: NMDA receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: NMDA receptor antagonist (memantine)
Study: 16035127
Drug: Timed bright
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timed bright light therapy (morning or afternoon exposure at > or = 2500 lux)
Study: 11831542
Drug: Oxycodone 5
Normalized name: oxycodone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 5 mg/325 mg
Study: 11831542
Drug: Oxycodone 7.5
Normalized name: oxyCODONE 7.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 7.5 mg/500 mg
Study: 11831542
Drug: Oxycodone 10
Normalized name: oxycodone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 10 mg/650 mg
Study: 2188165
Drug: Sublingual captopril
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual captopril (SLC) 25 mg
Study: 2188165
Drug: Sublingual nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual nifedipine (SLN) 10 mg
Study: 18827360
Drug: Extended-release (ER)
Normalized name: Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release (ER) formulations of glipizide (fast, moderate, slow)
Study: 18827360
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) formulation of glipizide
Study: 10688396
Drug: Etanercept 10
Normalized name: Etanercept 10 mg powder for solution for injection vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 10 mg
Study: 8325622
Drug: Terlipressin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (2 mg and then 1 mg/4 hr over 24 hr) and transdermal nitroglycerin (10 mg/12 hr over 24 hr)
Study: 8325622
Drug: Octreotide (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (continuous intravenous infusion of 25 micrograms/hr over 12 hr and then 100 micrograms at hr 12 and hr 18 subcutaneously)
Study: 27807890
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg extended-release aspirin
Study: 24375476
Drug: Topical anesthetic
Normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical anesthetic application for 30 minutes
Study: 24375476
Drug: Topical anesthetic
Normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical anesthetic application for 60 minutes
Study: 24375476
Drug: Topical anesthetic
Normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical anesthetic application for 30 minutes vs 60 minutes
Study: 23250175
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of preprocedural mouthrinsing with 0.2% chlorhexidine gluconate and high volume evacuator attachment
Study: 12068251
Drug: 0.4 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g/kg ethanol
Study: 11602546
Drug: Pravastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (40 mg daily for 3 months)
Study: 7938398
Drug: Sublingual captopril
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual captopril
Study: 27617366
Drug: One of
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One of four text versions of a warning label (e.g., SAFETY WARNING: Drinking beverages with added sugar(s) contributes to obesity, diabetes, and tooth decay)
Study: 24899156
Drug: Fresh avocado
Normalized name: Avocado
DrugBank: Avocado (DB10504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh avocado (23 g of lipid) with high-β-carotene tomato sauce (33.7 mg of β-carotene)
Study: 24899156
Drug: Fresh avocado
Normalized name: Avocado
DrugBank: Avocado (DB10504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh avocado (23 g of lipid) with raw carrots (27.3 mg of β-carotene and 18.7 mg of α-carotene)
Study: 24899156
Drug: Fresh avocado
Normalized name: Avocado
DrugBank: Avocado (DB10504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh avocado (23 g of lipid)
Study: 15935646
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: CI 10 mL/h, PCEA bolus 6 mL, 8‐min lockout
Study: 15935646
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: CI 10 mL/h, PCEA bolus 12 mL, 16‐min lockout
Study: 15935646
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: CI 15 mL/h, PCEA bolus 6 mL, 8‐min lockout
Study: 15935646
Drug: Group D:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D: CI 15 mL/h, PCEA bolus 12 mL, 16‐min lockout
Study: 8988070
Drug: Nebulized budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nebulized budesonide (2 mg twice daily)
Study: 8988070
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (30 mg once daily)
Study: 29878869
Drug: 400 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 µg salbutamol administered before exercise
Study: 27559041
Drug: Prasugrel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (60 mg loading dose / 10 mg maintenance dose once daily)
Study: 27559041
Drug: Ticagrelor (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (180 mg loading dose / 90 mg maintenance dose twice daily)
Study: 25344328
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) 0.5 g/kg plus standard treatment
Study: 25344328
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo plus standard treatment
Study: 16342925
Drug: Simulated imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulated imatinib treatment (80% favorable survival times)
Study: 16342925
Drug: Simulated imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulated imatinib treatment (65% favorable survival times)
Study: 16342925
Drug: Simulated imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulated imatinib treatment (50% favorable survival times)
Study: 9649993
Drug: Minimal-flow anaesthesia
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal-flow anaesthesia (0.5 L min-1 fresh gas inflow)
Study: 9649993
Drug: Higher-flow anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-flow anaesthesia (3 L min-1 fresh gas flow)
Study: 23123375
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg extended release oxybutynin daily
Study: 31310186
Drug: Family phone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family phone calls and/or visits with patients, attendance at family therapy sessions, communication with inpatient staff about services available to families
Study: 28337872
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ropivacaine (0.50%)
Study: 28337872
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg ropivacaine (0.50%)
Study: 28337872
Drug: 14 mg
Normalized name: iodine 0.14 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 mg ropivacaine (0.50%)
Study: 26159013
Drug: Peitu Shengjin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peitu Shengjin Recipe (PSR), one dose per day
Study: 26159013
Drug: Seretide (50/500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seretide (50/500 µg), twice per day
Study: 10894991
Drug: L‐dopa +
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐dopa + lisuride
Study: 10894991
Drug: L‐dopa alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐dopa alone
Study: 4059296
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g triletide
Study: 4059296
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g triletide
Study: 4059296
Drug: Dose correlation
Normalized name: diphenhydramine hydrochloride Oral Solution [Correct Dose Childrens Allergy Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose correlation
Study: 29945918
Drug: Risankizumab 18
Normalized name: RISANKIZUMAB 180 mg in 1.2 mL SUBCUTANEOUS INJECTION, SOLUTION [Skyrizi]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risankizumab 18 mg
Study: 29945918
Drug: Risankizumab 90
Normalized name: Risankizumab 90.361 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risankizumab 90 mg
Study: 25006678
Drug: Ergocalciferol (50,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ergocalciferol (50,000 IU weekly for one month followed by 50,000 IU monthly)
Study: 22643537
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib mesylate (400 mg/day for 36 months)
Study: 22643537
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib mesylate (400 mg/day for 12 months)
Study: 20391952
Drug: Octatropine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octatropine plus diazepam (Valpinax) 40 mg/2.5 mg twice daily for 6 weeks
Study: 18272290
Drug: Nicotine (Nicorette
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (Nicorette 2 mg gum)
Study: 15721731
Drug: 500‐mg paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500‐mg paracetamol + 75‐mg caffeine
Study: 15721731
Drug: 500‐mg paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500‐mg paracetamol + 125‐mg caffeine
Study: 9861379
Drug: Chloroquine syrup
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine syrup (25 mg/kg)
Study: 7898741
Drug: Conventional antiepileptic
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antiepileptic drugs (monotherapy)
Study: 7898741
Drug: New antiepileptic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New antiepileptic agents
Study: 2146130
Drug: Etodolac (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac (200 to 300 mg b.i.d. or 200 mg t.i.d.)
Study: 2146130
Drug: Etodolac (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac (200 mg b.i.d.)
Study: 2146130
Drug: Etodolac (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac (50 to 200 mg b.i.d.)
Study: 2146130
Drug: Naproxen (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (250 to 375 mg b.i.d.)
Study: 374176
Drug: Motilin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Motilin infusion (0.34 pmol/kg/min for 60 min, followed by 0.68 pmol/kg/min for 60 min)
Study: 374176
Drug: Motilin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Motilin infusion (high dose)
Study: 374176
Drug: Motilin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Motilin infusion (low dose)
Study: 26631103
Drug: 150-mg Artemisia
Normalized name: Artemisia vulgaris
DrugBank: Artemisia vulgaris root (DB14170)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150-mg Artemisia annua extract (ART) twice daily (BD)
Study: 26631103
Drug: 300-mg Artemisia
Normalized name: Artemisia vulgaris
DrugBank: Artemisia vulgaris root (DB14170)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300-mg Artemisia annua extract (ART) twice daily (BD)
Study: 23611363
Drug: Individual daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual daily pain treatment with acetaminophen, extended release morphine, buprenorphine transdermal patch, and/or pregabaline for 8 weeks